The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

DEAR DR. ROACH: You recently wrote about colitis, aka inflammation of the colon. Could you please explain how to treat and prevent it? -- M.C. ANSWER: “Colitis” does mean inflammation of the colon, ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

Whether it's a dull ache, sharp cramp or persistent discomfort, most of us have experienced some degree of stomach pain throughout our lives. While something as mild as indigestion, gas, bloating or ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

Johnson & Johnson has announced a positive opinion from the CHMP recommending expanded marketing authorisation for TREMFYA ...

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of ...

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...

Researchers at the University of Michigan Health Rogel Cancer Center discovered a new mechanism for eliminating one of the main side effects of immunotherapy treatment: colitis. Immunotherapy is used ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...